Cardiol Therapeutics Inc. (TSE:CRDL - Get Free Report)'s stock price traded up 3.4% on Wednesday . The company traded as high as C$1.57 and last traded at C$1.50. 159,808 shares traded hands during mid-day trading, an increase of 60% from the average session volume of 99,597 shares. The stock had previously closed at C$1.45.
Cardiol Therapeutics Stock Down 1.3%
The firm has a market capitalization of C$124.76 million, a price-to-earnings ratio of -3.10 and a beta of 0.95. The business's 50-day moving average is C$1.68 and its two-hundred day moving average is C$1.64. The company has a debt-to-equity ratio of 1.59, a quick ratio of 6.84 and a current ratio of 2.49.
Cardiol Therapeutics Company Profile
(
Get Free Report)
Cardiol Therapeutics Inc NASDAQ: CRDL TSX: CRDL is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.
See Also
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
